TOTAL VOLUME:
$95.3b
24H VOL:
$112,723,433
24H TRANSACTIONS:
920,787,070
OPEN INTEREST:
$1,981,470,087
799,284
Markets across
13,560
events
MATCHED EVENTS:
775
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
FDA approves Celcuity's Gedatolisib? Odds & Prediction Markets
71%
chance
Time left: 03d:17h:28m
FDA approves Celcuity's Gedatolisib?
$
$20
$50
$100
$500
Description
As of market creation, the FDA's expected decision date for the specified application is July 17, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Celcuity's Gedatolisib as a treatment for HR+/HER2-, PIK3CA wild-type advanced breast cancer by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 17, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Celcuity's Gedatolisib as a treatment for HR+/HER2-, PIK3CA wild-type advanced breast cancer by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-time trader conviction and financial incentives. While equity analysts and biotech research firms publish probability estimates based on clinical trial data and regulatory timelines, this market prices approval odds through continuous trading. Traders with deep domain knowledge or access to emerging trial results can move odds faster than published consensus. The market's implied probability reflects a crowd-sourced view that may lead or lag formal analyst updates, depending on information flow and trader positioning around Gedatolisib's development milestones.
On Polymarket, this market is priced through an automated market maker (AMM) model where traders buy and sell shares representing "FDA approves Celcuity's Gedatolisib" or the opposing outcome. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The price of approval shares reflects the probability implied by the ratio of liquidity pools; as traders buy approval shares, their price rises and the implied approval odds increase. Each transaction updates the pool balances, continuously repricing the market. Traders profit by buying low and selling high, or by holding shares until resolution. The current odds reflect the latest trading activity and cumulative market sentiment.
This market resolves around Jul 17, 2026, with the outcome confirmed once the FDA's decision on Gedatolisib is verifiable from credible public sources. Resolution hinges on whether Celcuity receives formal FDA approval for the drug candidate by the deadline. Traders holding approval shares receive full payout if the agency grants approval; those holding rejection shares are paid out if the application is denied or withdrawn. The market's binary structure means there is no partial resolution—the outcome is either approval or non-approval as of the end date.
Key catalysts include clinical trial data releases, FDA meeting announcements, and regulatory feedback letters that signal approval likelihood. Positive Phase 2 or Phase 3 efficacy results typically boost approval odds, while safety concerns or trial setbacks can trigger sharp declines. FDA advisory committee meetings, if scheduled, often generate significant price movement as experts weigh the evidence publicly. Competitor approvals in the same therapeutic area may also influence trader sentiment. Earnings calls where Celcuity management discusses regulatory strategy, manufacturing readiness, or timeline updates can shift market expectations. Any public FDA communication regarding the application status will likely trigger immediate repricing.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.